Creso Pharma (ASX:CPH, FRA:1X8) has entered into an agreement with Burleigh Heads Cannabis to distribute their CannaQIX®50 CBD lozenges in Australia.
The CannaQIX®50 CBD lozenge is designed to support the management of chronic pain, although the product will be distributed under the CDA branding and does not yet have all regulatory approvals.
Burleigh Heads Cannabis is the wholesale and distribution arm of Cannabis Doctors Australia (CDA), an organisation that provides assistance in the process of applying, prescribing and sourcing medical cannabis – for both patients and medical professionals.
Dr Miri Halperin Wernli, Creso Pharma’s CEO said, “In a short time, Burleigh Heads Cannabis and CDA have build a formidable distribution network providing much needed access to Australians seeking the therapeutic properties of medicinal cannabis. Whilst our collaboration will focus initially on the introduction of CannaQIX®50, we are looking forward to working together on the introduction of a range of pipeline therapeutic products to be produced by Creso at our production facilities globally.”
Over the past 12 months, Creso has been forming strategic distribution agreements for their CBD products across the globe – most recently in New Zealand and Sri Lanka.
